Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Arthur Schueler

Family Medicine St Peter, MN Doctor of Osteopathy

NPI 1114991833 CMS profile 822093

1900 N Sundise Drive, Suite 200, St Peter, MN 56082

Open in the dashboard

General payments

$1,154

76 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Arthur Schueler of St Peter, MN is reported in the CMS Open Payments database as having received $1,154 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $97 5
2021 General $71 4
2020 General $151 10
2019 General $835 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arthur Schueler
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Arthur Schueler were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Arthur Schueler Family Medicine median Middle half National median
2019 $835 $150 $41–$543 $163
2020 $151 $120 $32–$415 $114
2021 $71 $137 $35–$551 $132
2022 $97 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novo Nordisk Inc $478 32 payments
  2. AstraZeneca Pharmaceuticals LP $133 10 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $114 7 payments
  4. Novartis Pharmaceuticals Corporation $86 5 payments
  5. Amgen Inc. $72 4 payments
  6. Merck Sharp & Dohme Corporation $57 4 payments
  7. Pfizer Inc. $52 4 payments
  8. Abbott Laboratories $44 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $37 2 payments
  10. Janssen Pharmaceuticals, Inc $23 2 payments
  11. Other $58 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,148 75 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2022
  1. Ozempic $348 20 payments
  2. RYBELSUS $191 11 payments
  3. FARXIGA $133 10 payments
  4. ENTRESTO $64 4 payments
  5. Repatha $59 3 payments
  6. AIMOVIG $56 3 payments
  7. ELIQUIS $52 4 payments
  8. CHANTIX $52 4 payments
  9. Saxenda $50 7 payments
  10. FreeStyle Libre 2 $44 2 payments
  11. Other $587 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

8,281

Median for Family Practice: 1,826

Drug cost

$499,160

Median for Family Practice: $120,094

Branded share of claims

18.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 103 $105,432
Xarelto Rivaroxaban Brand 88 $85,629
Ozempic Semaglutide Brand 48 $51,688
Jardiance Empagliflozin Brand 34 $34,096
Orgovyx Relugolix Brand 11 $29,015
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $28,619
Trulicity Dulaglutide Brand 16 $20,791
Mounjaro Tirzepatide Brand 16 $16,541
Repatha Sureclick Evolocumab Brand 24 $13,469
Myrbetriq Mirabegron Brand 14 $5,855

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$67,923

Of which drugs: $4,727

Medicare patients

286

Average age 75

Services billed

1,324

137 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 40%
Atrial fibrillation 33%
Chronic kidney disease 32%
Diabetes 26%
Heart failure 25%
Ischemic heart disease 22%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 20 20 $1,602

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record